Startup | August 30, 2024
Bayer awards incubator opportunity to Genvor
Critical resources will help Genvor to grow and scale biological crop protection products and innovative trait technologies
Critical resources will help Genvor to grow and scale biological crop protection products and innovative trait technologies
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo
Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT
Sleep disturbances are among the most frequent and disruptive symptoms associated with menopause which can impact women’s health and quality of life
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
EBITDA before special items falls 1.3 percent to € 4.41 billion
The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Subscribe To Our Newsletter & Stay Updated
